Amgen's Q3 results revealed continued challenges from ESA headwinds, impacting the stock's short-term trajectory. The reduced revenue and managed expenses reflect the evolving market dynamics. Meanwhile, positive trial results and submissions for new treatments are encouraging. The stock will likely experience pressure in the short term, but the pipeline's progress hints at potential medium-term gains.

0